By David Wallace Silence Therapeutics reported that divesiran met the primary endpoint of the randomized Phase 2 SANRECO trial. Among 48 phlebotomy-dependent polycythemia vera patients, 88% of those receiving divesiran maintained hematocrit below 45% without phlebotomy during weeks 18 through 36, compared with 19% on placebo. The difference was statistically significant. What the Phase 2 […]
What Are The Key Factors in Predicting Polycythemia Vera Progression?
by David Wallace A new study has shed light on the factors that may predict polycythemia vera (PV) disease progression. The REVEAL study, presented at the 2024 European Hematology Association Congress, has identified five key characteristics that could help doctors better understand which patients are at higher risk of their condition worsening over time. Polycythemia […]
Theories on Treatment of Polycythemia Vera with Interferon-β
Simple Summary The myeloproliferative neoplasms (MPNs) are chronic blood cancers characterized by elevated blood cell counts and, after decades, the development of bone marrow failure. Blood clots are common and contribute massively to the symptom burden. Treatment with interferon (IFN) alpha-2 normalizes elevated blood cell counts within weeks to months. This treatment has been used […]
Real-World Treatments and Thrombotic Events in U.S. based Polycythemia Vera Patients
Abstract Polycythemia vera (PV) is a myeloproliferative neoplasm associated with increased risk of thrombotic events (TE) and death. Therapeutic interventions, phlebotomy and cytoreductive medications, are targeted to maintain hematocrit levels < 45% to prevent adverse outcomes. This retrospective observational study examined medical and pharmacy claims of 28,306 PV patients initiating treatment for PV in a data period […]